Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -12.79% and -39.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?